Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31693660 | 0.92 | CYP2C9 (0.46) | USP2SMN1; SMN2TSHRALOX15EPHX2 | |
| SCHEMBL21807209 | 0.90 | TSHR (0.45) | USP2SMN1; SMN2TSHRALOX15EPHX2 | |
| SCHEMBL21963957 | 0.88 | USP2 (0.43) | USP2SMN1; SMN2TSHRALOX15EPHX2 | |
| SCHEMBL9963090 | 0.86 | USP2 (0.41) | USP2SMN1; SMN2TSHRALOX15EPHX2 | |
| SCHEMBL9963088 | 0.85 | TSHR (0.40) | USP2SMN1; SMN2TSHRALOX15EPHX2 | |
| SCHEMBL3790394 | 0.84 | USP2 (0.47) | USP2SMN1; SMN2TSHRALOX15EPHX2 | |
| SCHEMBL3648747 | 0.83 | USP2 (0.46) | USP2SMN1; SMN2TSHRALOX15EPHX2 | |
| SCHEMBL15437342 | 0.82 | TSHR (0.42) | USP2SMN1; SMN2TSHRALOX15EPHX2 | |
| SCHEMBL31566620 | 0.81 | USP2 (0.39) | USP2SMN1; SMN2TSHRALOX15EPHX2 | |
| SCHEMBL4287443 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2TSHRALOX15EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| EP-4100407-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | Newave Pharmaceutical Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022204109-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| CN-114007695-A | As AM2Heterocyclic spiro-compounds as receptor inhibitors | 谢菲尔德大学 | 2022-02-01 | — | — | CN | disclosed |
| WO-2021158948-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-2872508-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2018-08-29 | — | — | EP | disclosed |
| US-9309243-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2016-04-12 | — | — | US | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | USP2 4272/4885SMN1; SMN2 411/4885TSHR 660/4885 |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, NR3C2 | USP2 4419/4885SMN1; SMN2 1891/4885TSHR 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.